BioNotebook: Puma CEO sees sale as option, Tesaro drops, Can-Fite gains on study results
This article was originally published in Scrip
Executive Summary
'Tis the season to dump good and bad news just before the holidays. Despite the upbeat headline in the company's press release, Tesaro reported mixed results for a late-stage experimental drug. Can-Fite BioPharma had better news. And Puma Biotechnology's CEO, a man with a love of big cat names, vows to do what's right for his shareholders.